Clinical implications of HBsAg quantification in patients with chronic hepatitis B

Saudi Journal of Gastroenterology

Volumn 18, Issue 2, 2012, Pages 81-86

  Viganò, Mauro ^a   Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic hepatitis B; HBsAg quantification; interferon

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEROCONVERSION;

DNA, VIRAL; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; POLYETHYLENE GLYCOLS; PYRIMIDINONES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84858955605     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.93805     Document Type: Review

References (42)

1. Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009;49(5 Suppl):S22-7.
2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42.
3. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - A core group report. J Hepatol 2011;55:1121-31.
4. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009;3:S5-15.
5. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010;52:475-7.
6. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B Virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50.
7. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot- Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
8. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007;12:73-82. (Pubitemid 46340428)
9. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol 2010;52:508-13.
10. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22.
11. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52:1232-41.
12. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-9.
13. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90.
14. Martinot-Peignoux M, Lada O, Cardoso AC, Lapalus M, Boyer N, Ripault MP, et al. Quantitative HBsAg: A new specific marker for the diagnosis of HBsAg inactive carriage. Hepatology 2010;52:992A.
15. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-25, 525.e1-2.
16. Chan HL, Wong GL, Tse C, Chan H, Wong VW. Definition of inactive hepatitis B carrier by serum HBsAg and HBV DNA levels - A long-term follow up study on HBsAs seroclearance. J Hepatol 2011;54;S144.
17. Yakut M, Bektas M, Seven G, Kabaçam G, Karatayli E, Karatayli S, et al. Characterization of the inactive HBsAg carriers state with 3 year follow up. J Hepatol 2011;54;S159.
18. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alphainterferon therapy. Antiviral Res 1994;23:251-7. (Pubitemid 24122302)
19. Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-53.
20. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7.
21. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 2011;53:1054-5.
22. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: Association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011. [In Press]
23. Gane E, Jia J, Han K, Tanwandee T, Chuang WL, Marcellin P, et al. Neptune study: On-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol 2011;54;S31.
24. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010;32:1323-31.
25. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Popescu M, Farci P, et al. On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year posttreatment, subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a. Hepatol Int 2010;4:151.
26. Lampertico P, Viganò M, Galeota Lanza A, Sagnelli E, Fasano M, Di Marco V, et al. PegBeLiver study: HBsAg decline at week 24 of extended peginterferon alfa-2a (Peg-IFNá-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients. J Hepatol 2011;54:S293.
27. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa- 2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61.
28. Rijckborst V, Hansen B, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. Hepatology 2010;52:479A.
29. Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. A response guided approach to peg-interferon alfa-2a at weeks 12 and 24 improves response rates in HBeAg-negative, genotype D chronic hepatitis B patients. Hepatology 2011;54:1021A.
30. Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, et al. Response to peginterferon alfa-2a in HBeAg negative CHB: Baseline and on-treatment kinetics of HBsAg serum levels vary according to HBV genotype. Hepatology 2011;54:1059A.
31. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha-2a. Antivir Ther 2009;14:1183-8.
32. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005;75:235-9. (Pubitemid 40053734)
33. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20.
34. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48:22-6.
35. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54.
36. Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010;44:653-7.
37. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
38. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol 2011;54:740A.
39. Brunetto M, Moriconi F, Cavallone D, Oliveri F, Maina AM, Ciccorossi P, et al. Reduction in serum HBsAg level in patients with chronic epatiti B infected with genotype D induced by (Pegylated) interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study. Hepatology 2007;46:679A.
40. Iavarone M, Lampertico P, Viganò M, Facchetti F, Lunghi G, Melotti S, et al. Progressive decline of HBsAg titers in long term responders to nucleos(t)ides analogue therapy for chronic hepatitis B. J Hepatol 2009;50:S331.
41. Zoutendijk R, Hansen BE, Van Vuuren AJ, Boucher CA, Janssen HL. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleos(t)ide analogue therapy for chronic hepatitis B. Hepatology 2010;52:381A.
42. Chevaliez S, Hezode C, Grare M, Pawlotsky JM. Long-term monitoring of HBsAg kinetics and prediction of HBsAg clearance in patients with chronic hepatitis B treated with nucleoside/nucleotide analogues. Hepatology 2010;52:374A.